PharmaVitae 2005: Genentech Global and US Analysis
Price:
$3 800.00
Introduction
This analysis examines the current position and future outlook for Genentech in the biotechnology sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Reasons to Purchase
Benchmark Genentech’s performance against key rivals in the biotechnology sector
Gain understanding as to why Genentech’s ethical sales are forecast to grow from $3,749m in 2004 to $9,192m in 2010
Gain insight into why Genentech should drive long-term growth of their oncology franchise by developing fully human monoclonal antibody products
